Flag of the European Union EU Clinical Trials Register Help

Clinical trials for DNA methylation in cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    45 result(s) found for: DNA methylation in cancer. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2013-005086-40 Sponsor Protocol Number: J1214 Start Date*: 2014-05-21
    Sponsor Name:Sidney kimmel Comprehensive Cancer Center at Johns Hopkins
    Full Title: A multi-institutional open label, trial evaluating the efficacy of Gemcitabine and Docetaxel in patients with relapsed or refractory metastatic colorectal adenocarcinoma with methylated CHFR and/or...
    Medical condition: relapsed or refractory metastatic colorectal adenocarcinoma with methylation of CHFR and/or microsatellite instability
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010030 Colorectal cancer recurrent PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-001407-23 Sponsor Protocol Number: GEICAM/2015-06 Start Date*: 2017-01-05
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: A Phase II Clinical Trial to analyse Olaparib Response in patients with BRCA1 and/or 2 Promoter Methylation Diagnosed of Advanced Breast Cancer (COMETA-Breast study).
    Medical condition: Patients with advanced triple negative breast cancer (TNBC) with BRCA1 and/or BRCA2 promoter methylation assessed in DNA from metastatic lesions and absence of BRCA1 and 2 germline mutations.
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2018-000155-41 Sponsor Protocol Number: 1 Start Date*: 2019-01-10
    Sponsor Name:Department of Medical and Clinical Genetics, University of Helsinki
    Full Title: The effect of vitamin C on the gene methylation load in patients with TET2 mutations
    Medical condition: germline TET-2 gene mutation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000689-30 Sponsor Protocol Number: Pem-NSCLC Start Date*: 2018-08-02
    Sponsor Name:Med. Univ. Wien, Klinik f. Innere Med. I, Onkologie
    Full Title: Expression/DNA methylation of cancer testis antigens may predict response to pembrolizumab in pretreated NSCLC patients
    Medical condition: untreated patients with adenocarcinoma of the lung of advanced stage
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2006-002324-41 Sponsor Protocol Number: PH2/051 Start Date*: 2006-11-30
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK Randomised Multicentre Phase II Trial of the DNA-hypomethylating Agent, 5-Aza-2'-deoxycytidine(Decitabine) given intravenously in Combination with Carboplatin, versus Carboplat...
    Medical condition: Progressive, advanced ovarian cancer
    Disease: Version SOC Term Classification Code Term Level
    8.1 10033128 Ovarian cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003977-24 Sponsor Protocol Number: SGI-110-03 Start Date*: 2014-03-20
    Sponsor Name:Astex Pharmaceuticals Inc
    Full Title: A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment with Sorafenib
    Medical condition: Advanced Hepatocellular Carcinoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-005268-41 Sponsor Protocol Number: HE5A/15 Start Date*: 2016-04-25
    Sponsor Name:Hellenic Cooperative Oncology Group
    Full Title: Phase ΙΙ (window) preoperative study of olaparib with or without cisplatin or no treatment in patients with histologically proven squamous cell carcinoma of the head and neck who are candidates for...
    Medical condition: Histologically proven operable squamous cell carcinoma of the head and neck.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003689-41 Sponsor Protocol Number: CRAD001YGB11 Start Date*: 2012-11-19
    Sponsor Name:Novartis Pharmaceuticals UK Ltd
    Full Title: A Phase IV multicentre, open label study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with everolimus (RAD001) in combination with e...
    Medical condition: oestrogen receptor positive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-004418-17 Sponsor Protocol Number: I-BCT-1 Start Date*: 2014-05-07
    Sponsor Name:Oslo University Hospital
    Full Title: Improved breast cancer therapy (I-BCT-1) in the neoadjuvant and metastatic setting: A phase 2 clinical trial protocol studying biological rationale for the optimal selection of treatment regimens.
    Medical condition: breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2010-023584-17 Sponsor Protocol Number: RAS-AZIC Start Date*: 2012-08-31
    Sponsor Name:Universität Leipzig
    Full Title: Response-Adapted Sequential Azacitidine And Chemotherapy in Patients > 60 Years Old With Newly Diagnosed AML Eligible for Chemotherapy and allogeneic hematopoietic cell transplantation: A Multicent...
    Medical condition: acute myeloid leukeamia
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-000586-19 Sponsor Protocol Number: 307971 Start Date*: 2005-07-25
    Sponsor Name:Bayer Schering Pharma AG
    Full Title: Phase-II study to investigate the efficacy and safety of ZK 219477 as second-line therapy in patients with Stage IIIB or Stage IV non-small-cell lung cancer (NSCLC)
    Medical condition: Non small cell lung cancer (NSCLC) stage IIIB or stage IV
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-003530-13 Sponsor Protocol Number: 18072011 Start Date*: 2011-12-20
    Sponsor Name:Brighton & Sussex University Hospitals NHS Trust
    Full Title: Randomised phase II window study of short-term preoperative treatment with the PI3K inhibitor GDC-0941 plus Anastrozole versus Anastrozole alone in patients with ER-positive primary breast cancer
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006206 Breast carcinoma NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-003003-31 Sponsor Protocol Number: EORTC 26082 – 22081 Start Date*: 2009-12-01
    Sponsor Name:EORTC Headquarters
    Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra...
    Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter
    Disease: Version SOC Term Classification Code Term Level
    13.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001447-40 Sponsor Protocol Number: 28UCS2019 Start Date*: 2020-06-29
    Sponsor Name:ENTE OSPEDALIERO OSPEDALI GALLIERA
    Full Title: Pilot Study of Daily Exemestane in Women with Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer
    Medical condition: Complex Atypical Hyperplasia of the Endometrium / Endometrial Intraepithelial Neoplasia or Low Grade Endometrial Cancer in post-menopausal women
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014755 Endometrial hyperplasia PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001001-14 Sponsor Protocol Number: IEO240 Start Date*: 2015-10-07
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: ¿A randomized placebo controlled phase II study with metformin in metabolic-unbalanced breast cancer survivors at higher risk for recurrence (MetBreCS)¿
    Medical condition: Metabolic-unbalanced breast cancer survivors at higher risk for recurrence (triple negative breast cancer, luminal B Her2 positive, non luminal HER2 positive)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006190 Breast cancer invasive NOS LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003319-12 Sponsor Protocol Number: ICR-CTSU-2014-10046 Start Date*: 2015-03-27
    Sponsor Name:The Royal Marsden NHS Foundation Trust [...]
    1. The Royal Marsden NHS Foundation Trust
    2. The Insitute of Cancer Research
    Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO)
    Medical condition: Primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-002686-30 Sponsor Protocol Number: CEP-AZ-SH-02 Start Date*: 2009-04-15
    Sponsor Name:Christie Hospital NHS Foundation Trust
    Full Title: Assessment of the effects of the specific endothelin-A antagonist ZD4054 on prostate cancer biomarkers in patients with castrate-resistant metastatic disease
    Medical condition: Prostate cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036909 Prostate cancer metastatic LLT
    Population Age: Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003335-29 Sponsor Protocol Number: SIOPEATRT01 Start Date*: 2021-04-15
    Sponsor Name:German Pediatric Oncology Group, GPOH gGmbH
    Full Title: An international prospective umbrella trial for children with atypical teratoid/rhabdoid tumours (ATRT) including A randomized phase III study evaluating the non-inferiority of three courses of hig...
    Medical condition: atypical teratoid/rhabdoid tumours (ATRT)
    Disease:
    Population Age: Newborns, Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: DE (Ongoing) NO (Trial now transitioned) NL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-009916-33 Sponsor Protocol Number: 00332/AMLSG14-09 Start Date*: 2011-05-13
    Sponsor Name:University Medical Center Freiburg
    Full Title: Prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic...
    Medical condition: Patients older than 60 years with acute myeloid leukemia according to WHO (≥ 20 % blasts in the peripheral blood (pB) or bone marrow (BM)) not qualifying for, or not consenting to, standard remissi...
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10000886 Acute myeloid leukemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2019-000935-15 Sponsor Protocol Number: PRODIGE70-CIRCULATE Start Date*: 2019-09-10
    Sponsor Name:Centre Hospitalier Universitaire (CHU) de Dijon
    Full Title: CIRCULATE- CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
    Medical condition: stage II colon cancer, after tumour resection
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 19:37:24 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA